|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0085405,
umls-concept:C0086045,
umls-concept:C0123759,
umls-concept:C0175630,
umls-concept:C0185117,
umls-concept:C0205127,
umls-concept:C0205216,
umls-concept:C0301625,
umls-concept:C0332281,
umls-concept:C0392756,
umls-concept:C0439230,
umls-concept:C0439662,
umls-concept:C1308752,
umls-concept:C1332700,
umls-concept:C1367714,
umls-concept:C1522577,
umls-concept:C1706327,
umls-concept:C1879547,
umls-concept:C2911684
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-3-30
|
|
pubmed:abstractText |
It has been suggested that patients who initiate highly active antiretroviral therapy (HAART) late in their course of infection may have suboptimal CD4 T-cell gains, persistent alterations in T-cell subsets and residual inflammation. To address this issue, we carried out a comprehensive 48-week immunological study in HIV-infected patients who had experienced failures of prior therapies, had low CD4 cell counts, and were receiving enfuvirtide-based salvage therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1468-1293
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
65-77
|
|
pubmed:meshHeading |
pubmed-meshheading:20500532-Adolescent,
pubmed-meshheading:20500532-Adult,
pubmed-meshheading:20500532-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:20500532-CD4-Positive T-Lymphocytes,
pubmed-meshheading:20500532-Chemokine CXCL10,
pubmed-meshheading:20500532-HIV Envelope Protein gp41,
pubmed-meshheading:20500532-HIV Fusion Inhibitors,
pubmed-meshheading:20500532-HIV Infections,
pubmed-meshheading:20500532-HIV-1,
pubmed-meshheading:20500532-Humans,
pubmed-meshheading:20500532-Interleukin-12,
pubmed-meshheading:20500532-Longitudinal Studies,
pubmed-meshheading:20500532-Male,
pubmed-meshheading:20500532-Middle Aged,
pubmed-meshheading:20500532-Peptide Fragments,
pubmed-meshheading:20500532-Receptors, CCR5,
pubmed-meshheading:20500532-Salvage Therapy,
pubmed-meshheading:20500532-Viral Load,
pubmed-meshheading:20500532-Virus Replication,
pubmed-meshheading:20500532-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
The suppression of immune activation during enfuvirtide-based salvage therapy is associated with reduced CCR5 expression and decreased concentrations of circulating interleukin-12 and IP-10 during 48 weeks of longitudinal follow-up.
|
|
pubmed:affiliation |
Infectiology Unit, University Nice Sophia-Antipolis, Nice, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
